Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
7 evidence topics · 6 sources
Summary
- Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
- Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
- Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
- Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
- Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.
Guideline treatment goals: PASI 75 minimum and PASI 90, absolute PASI below 2, or DLQI of 1 or less as the desired goal
“The fundamental goal of any therapy is to achieve complete clearance of symptoms – that is, the absence of cutaneous symptoms of psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, this goal is not realistically achievable in all patients at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the end of the induction period, a PASI 75 response is the minimum target, which should be controlled for at regular intervals during the course of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reaching a PASI 90 response or an absolute PASI <2 or DLQI ≤ 1 should be the desired treatment goal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-to-target response thresholds: BSA of 1% or less at 3 months and every 6 months
“The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The target response at 3 months postinitiation was BSA 1% or less.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The target response at every 6 months maintenance evaluation is BSA 1% or less.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to response and timing of the treatment goal assessment
“For treatments with a fast onset of action, treatment goals should be controlled for at the end of the induction therapy after 10 to 12 weeks; for treatments with a slower onset of action, this should be done after 16 to 24 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These time frames may not always include the time of maximum therapeutic effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-five trials were included in the main analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life and symptom resolution at PASI 90, PASI 95, and PASI 100
“Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability with continuous risankizumab through week 304
“Of 897 patients enrolled in the LIMMitless study, 661 completed the study for a total of 4921.2 patient years of exposure to risankizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 304, 86.0% of patients achieved PASI 90, 54.2% achieved PASI 100, 84.7% achieved sPGA 0/1, and 76.3% achieved DLQI 0/1 (using modified nonresponder imputation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Durability with continuous secukinumab 300 mg through year 5
“At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote